Clinical Performance of Short Fiber Reinforced Resin Modified Glass

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This research proposal is introduced to clinically test short fiber reinforced glass ionomer material from GC Europe due to gap of knowledge present in this area. It is characterized by higher flexural strength compared to resin modified glass ionomer (RMGIC). Additionally, the short fibers provided effective toughening of the RMGIC matrix by a fiber bridging mechanism.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03501784` - Nobio Antimicrobial Particles Effect in a Split Mouth Model	N/A
Recruiting	`NCT06394440` - Clinical Evaluation of Self-Adhesive Bulk-Fill Composite Versus Conventional Nano-hybrid Composite in Cervical Cavities	N/A
Recruiting	`NCT05624008` - Clinical Performance of Bioceramic vs High Viscosity GIC for Cervical Restorations of Geriatric Patients	N/A

NCT number	NCT06185881
Study type	Interventional
Source	Cairo University
Contact
Status	Completed
Phase	N/A
Start date	March 1, 2022
Completion date	December 28, 2023

Clinical Performance of Short Fiber Reinforced Resin Modified Glass Ionomer Restorations in Cervical Carious Teeth (1y Randomized Clinical Trial)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms